Efficacy of buparvaquone as a therapeutic and clearing agent of Babesia equi of European origin in horses.
We evaluated the efficacy of buparvaquone in eliminating infection with Babesia equi of European origin in carrier horses and in splenectomized horses with experimentally induced acute infection. When administered at the rate of 5 mg/kg of body weight, IV, 4 times at 48-hour intervals, buparvaquone prompted rapid abatement of parasitemia. However, secondary and tertiary recrudescent parasitemias invariably returned with establishment of the carrier state. Buparvaquone, at the dosage evaluated, had transitory therapeutic efficacy against acute B equi infection in splenectomized horses, but was unable alone to clear carrier infection.
Zaugg
J L
JL
University of Idaho, Caine Veterinary Teaching and Research Center, Caldwell 83605.
Lane
V M
VM
D000208:Acute Disease; D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001403:Babesia / Q000276:immunology; D001404:Babesiosis / Q000188:drug therapy*; D002353:Carrier State / Q000188:drug therapy / Q000662:veterinary*; D003168:Complement Fixation Tests; D005260:Female; D005455:Fluorescent Antibody Technique; D006734:Horse Diseases / Q000188:drug therapy*; D006736:Horses; D007275:Injections, Intravenous / Q000662:veterinary; D008297:Male; D009285:Naphthoquinones / Q000008:administration & dosage / Q000627:therapeutic use*; D013156:Splenectomy / Q000662:veterinary
D000913:Antibodies, Protozoan; D000981:Antiprotozoal Agents; D009285:Naphthoquinones; C046326:buparvaquone